Assessment of protective effect of the losartan against cisplatin-induced nephrotoxicity in mice DOI Creative Commons
Selçuk Teke, Gülşen Bayrak, Erdem Ak

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: May 3, 2025

Abstract Cisplatin is widely used in pediatric oncology but limited by its dose-dependent nephrotoxicity. The renin–angiotensin–aldosterone system (RAAS) has been implicated cisplatin-induced renal injury. Losartan, an angiotensin II receptor blocker, may offer protection; however, effects on apoptosis and regeneration this context remain unclear. This study aimed to investigate the potential protective role of losartan against nephrotoxicity, specifically assessing impact tubular regeneration. Fifteen female BALB/c mice were randomly assigned three groups ( n = 5 per group): Control, cisplatin (12.7 mg/kg, i.p., single dose), + (10 mg/kg/day, oral). Losartan was administered for nine consecutive days, starting 4 days before exposure. Histopathological examination, active caspase-3 immunostaining (for apoptosis), 5-bromo-2-deoxyuridine (BrdU) labeling cell proliferation) performed. Glomerular injury scores, H-scores, BrdU-positive counts statistically analyzed using Kruskal–Wallis H Mann–Whitney U tests. significantly increased glomerular p 0.006, 0.005, 0.006) scores 0.008, 0.007, 0.007), elevated expression 0.002), reduced 0.009) compared control. co-treatment 0.008) 0.009, v) decreased 0.009). Additionally, higher group both control 0.009), indicating enhanced mitigates nephrotoxicity suppressing promoting These findings support therapeutic RAAS inhibition preventing cisplatin-associated

Language: Английский

Assessment of protective effect of the losartan against cisplatin-induced nephrotoxicity in mice DOI Creative Commons
Selçuk Teke, Gülşen Bayrak, Erdem Ak

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: May 3, 2025

Abstract Cisplatin is widely used in pediatric oncology but limited by its dose-dependent nephrotoxicity. The renin–angiotensin–aldosterone system (RAAS) has been implicated cisplatin-induced renal injury. Losartan, an angiotensin II receptor blocker, may offer protection; however, effects on apoptosis and regeneration this context remain unclear. This study aimed to investigate the potential protective role of losartan against nephrotoxicity, specifically assessing impact tubular regeneration. Fifteen female BALB/c mice were randomly assigned three groups ( n = 5 per group): Control, cisplatin (12.7 mg/kg, i.p., single dose), + (10 mg/kg/day, oral). Losartan was administered for nine consecutive days, starting 4 days before exposure. Histopathological examination, active caspase-3 immunostaining (for apoptosis), 5-bromo-2-deoxyuridine (BrdU) labeling cell proliferation) performed. Glomerular injury scores, H-scores, BrdU-positive counts statistically analyzed using Kruskal–Wallis H Mann–Whitney U tests. significantly increased glomerular p 0.006, 0.005, 0.006) scores 0.008, 0.007, 0.007), elevated expression 0.002), reduced 0.009) compared control. co-treatment 0.008) 0.009, v) decreased 0.009). Additionally, higher group both control 0.009), indicating enhanced mitigates nephrotoxicity suppressing promoting These findings support therapeutic RAAS inhibition preventing cisplatin-associated

Language: Английский

Citations

0